close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

217.15 +1.72 (+0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,075,561
Open 216.75
Bid (Size) 217.09 (400)
Ask (Size) 217.36 (100)
Prev. Close 215.43
Today's Range 214.71 - 219.76
52wk Range 135.39 - 225.80
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to... 
Via MarketBeat
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill

Performance

YTD
+22.1%
+22.1%
1 Month
+3.1%
+3.1%
3 Month
+9.3%
+9.3%
6 Month
+18.5%
+18.5%
1 Year
+49.9%
+49.9%

More News

Read More
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Via StockStory
Topics Artificial Intelligence
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating ↗
Via Chartmill
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Via StockStory
Topics Artificial Intelligence
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Biogen Completes Acquisition of RayThera Inc.
From Biogen Inc.
Via GlobeNewswire
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
Via The Motley Fool
News headline image
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
Via StockStory
News headline image
Why Biogen Stock Topped the Market Today ↗
Via The Motley Fool

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 217.15
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 09/11/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 31.88B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 32B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.